Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway

Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway

Imidazolopiperazines (IZPs) are a class of compounds under clinical development for malaria, but their mechanism of action is unclear. Here, the authors show that IZPs inhibit the parasite’s secretory pathway, affecting protein trafficking and export.

Guardado en:
Detalles Bibliográficos
Autores principales: Gregory M. LaMonte, Frances Rocamora, Danushka S. Marapana, Nina F. Gnädig, Sabine Ottilie, Madeline R. Luth, Tilla S. Worgall, Gregory M. Goldgof, Roxanne Mohunlal, T. R. Santha Kumar, Jennifer K. Thompson, Edgar Vigil, Jennifer Yang, Dylan Hutson, Trevor Johnson, Jianbo Huang, Roy M. Williams, Bing Yu Zou, Andrea L. Cheung, Prianka Kumar, Timothy J. Egan, Marcus C. S. Lee, Dionicio Siegel, Alan F. Cowman, David A. Fidock, Elizabeth A. Winzeler
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/30325ebc8f1440eb95a7ef787cbdca69
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Imidazolopiperazines (IZPs) are a class of compounds under clinical development for malaria, but their mechanism of action is unclear. Here, the authors show that IZPs inhibit the parasite’s secretory pathway, affecting protein trafficking and export.

Ejemplares similares